June 2024

Guest blog by Aon...

Too many investments in life science companies are made without the appropriate human capital due diligence which can lead to problems post-deal in areas like poor talent retention and excessive salary costs. Aon’s Keaton Hoffman – Partner, Executive Compensation, Talent Solutions and Matthew Robinson – Life Science Industry Leader, explore why getting the human capital due diligence right is vital and where venture capital firms and the wider private equity market should be focusing.

By Tony Jones, CEO, One Nucleus

Jasmin Bannister, Business Development Manager

The life sciences industry plays a significant role in improving patient lives, but its operations can have a significant environmental impact. Energy consumption in labs is a major contributor and reducing this consumption is crucial for a more sustainable future.

Guest Blog Post by Cushman & Wakefield’s Kiran Patel (Associate, Head of National Office & Life Sciences Research) and Nick Blevins (Partner, Occupier Representation, Life Sciences).

Guest blog post by Molly Andrews, UK Dementia Research Institute; Priya Kalia, SciTribe; Miranda Weston-Smith, BioBeat

“There is an urgent need for innovative solutions and investment in the accurate diagnosis of neurodegenerative disease, and the development of effective treatment options.”
Professor Zoe Kourtzi, Professor of Computational Cognitive Neuroscience, University of Cambridge

Thoughts from Tony Jones, CEO One Nucleus.

Take part in our fun quiz designed to highlight the unique life science ecosystems of the UK, Minnesota, and North Carolina. After completing our quiz, why not join our complimentary webinar in collaboration with Blue Link Worldwide on 10 June on the topic of ‘USA Bio Invest - Coming to the USA’ to learn more about business opportunities for life science companies in these top US states.

Take our quiz!